The impact of intensive Statin therapy on periprocedural platelet parameters in older patients with

来源 :第八届北京五洲国际心血管病会议 | 被引量 : 0次 | 上传用户:youdong2010
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Objective To investigate the impact of intensive statin therapy on periprocedual platelet parameters in older patients with non-ST elevated acute coronary syndrome (NSTE-ACS) undergoing percutaneous coronary interventions (PCI).Methods A total of 138 patients over 65 year old with unstable angina pectoris or non ST segment elevation myocardial infarction in Beijing Anzhen Hospital of capital medical university were included.They were divided into conventional therapy group (received 20 mg atorvastatin per day, n=70) and intensive treatment group (received 80 mg load dose of atorvastatin then 40 mg per day, n=68) before PCI of 12 hours.Blood platelet count (PLT), mean platelet volume (MPV), platelet distribution (PDW) and platelet-large cell ratio (P-LCR) were measured at baseline, platelet parameter were measured after PCI of 1 and 5 days, and the platelet aggregation rate induced arachidonic acid and adenosine diphosphate were measured.Results There were no significant differences on platelet parameter after admission and PCI of 1 and 5 days between two groups (P>0.05).Compared with base line, platelet counts of conventional therapy group after PCI of 1 day significant decrease [(210±60) G/L vs (206±62) G/L, P=0.02], MPV levels [(10.6 ±0.9) fL vs (10.8 ±0.9) fL,P=0.001], PDW levels [(12.5±1.9) % vs (12.8± 1.9) %,P=0.03], and P-LCR levels [(32±8) % vs (30± 8) %, P=0.001] were significant increased, there were significant differences.There were no different on platelet parameters in intensive treatment group after PCI of 1 day compared with baseline (P>0.05).MPV [(10.6± 1.0) fL 比 (10.8±1.0) fL, P=0.02] andP-LCR [(30±9) %比 (31±8) %, P=0.02] of intensive treatment group were decreased significantly on 5 day after PCI.Conclusion Atorvastatin may beneficially inhibit the increasing of MPV, PDW, P-LCR results from PCI.This effect of atorvastatin could play a role in decrease platelet activation and reduce cardiovascular risk for NSTE-ACS patients.
其他文献
Objective To evaluate mitral annulus dynamic morphology over the cardiac cycle in patients with mitral valve prolapse(MVP) by using real-time three-dimensional transesophageal echocardiography (RT-3D-
Objective To evaluate mitral annulus geometry and function in the patients with mitral valve plasty by using real-time three-dimensional transesophageal echocardiography (RT-3D-TEE).Methods RT-3D-TEE
Objective To assess the clinical meaning ofEchogenic intracardiac focus in Fetuses by echocardiography.Methods The data of 310 fetuses diagnosed as Echogenic intracardiac focus by echocardiography wer
Objective The aims of this study were to analyze the features of mitral valve (MV) prolapse on the real-time 3-dimensional transesophageal echocardiography (RT-3D-TEE) and to explore the value of RT-3
会议
目的 分析影响首台择期手术延迟开始的原因.方法 调查我院2013年1~9月2458例择期手术病例,采用即时记录的方法,记录患者入室时间、手术开始时间,分别以8:20入室和9:00手术切皮时间为准,统计分析首台择期手术未准时开展的情况,对其原因进行分类和回顾性分析.结果 8:30按时入室的手术2177例,占总体的比例为72.34%, 9:00未准时开始的手术1400例,占总体的比例为46,52%,
Objective To prospectively investigate neurological complications after off-pump coronary artery bypass grafting (OPCABG), including the incidence and the risk factorsto study the correlation between
Objective This study was conducted to evaluate the impact of diabetes on patients with unprotected left main coronary artery (LMCA) disease treated with either percutaneous coronary intervention (PCI)
会议
AIM The purpose of this study was to study the influence of KCNE4 on potassium ion channel KCNQ 1 and HERG.Method We constructed KCNE4 expression plamids and performed the whole-cell patch-clamp recor
Objective Application of transesophageal echocardiography (TEE) guide the central type atrial septal defect closure during the minimally invasive surgery, evaluate the clinical value of TEE in the ope
Objective To observe diabetic patients after percutaneous coronary intervention (PCI) in the prevention of stent restenosis, prevention of in stent restenosis, clinical efficacy and safety of aspirin,